Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer

British Journal of Cancer

Volumn 76, Issue 6, 1997, Pages 812-818

  Solomayer, E F ^a   Diel, I J ^a   Wallwiener, D ^a   Bode, S ^a   Meyberg, G ^a   Sillem, M ^a   Gollan, Ch ^a   Kramer, M D ^a   Krainick, U ^a   Bastert, G ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; Micrometastasis; Prognostic factor; Tumour cell detection; Urokinase plasminogen activator (uPA)

Indexed keywords

ANTIBODY; CYCLOPHOSPHAMIDE; FLUOROURACIL; GLYCOPROTEIN; METHOTREXATE; TAMOXIFEN; UROKINASE;

ARTICLE; BONE MARROW METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; ILIAC CREST; IMMUNOCYTOCHEMISTRY; INTERPHASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 8544263800     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.467     Document Type: Article

References (47)

1. Bastert G, Eichler A and Kaul S (1987) Monoclonal antibodies against breast cancer. In Immune Deficient Animals in Biomedical Research, Rygaard K, Brünner N and Spang-Thomsen M. (eds), pp. 224-227. S Karger: Basle
2. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA and Smith HS (1994) The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866
3. Cantero D, Friess H, Deflorin J, Zimmermann A, Bründler M-A, Riesle E, Korc M and Büchler MW (1997) Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75: 388-395
4. Christensen L, Wiborg-Simonsen AC, Heegaard CW, Moestrup SK, Anderson JA and Andreasen PA (1996) Immunohistochemical localisation of urokinase-type plasminogen activator, type-1 plasminogen activator inhibitor, urokinase receptor and α(2)macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441-452
5. Collett D (1994) Modelling Survival Data in Medical Research. Chapman & Hall: London
6. Constantini V, Sidoni A, Deveglia R, Cattato OA, Welleza G, Ferri I, Bucciarelli E and Nenci GG (1996) Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor 1 is associated with breast cancer regression: an immunohistochemical comparison of normal, begnign and malignant breast tissues. Cancer 77: 1079-1088
7. Cote RJ, Rosen PP, Lesser ML, Old LJ and Osborne MP (1991) Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9: 1749-1756
8. Cox DR (1972) Regression models and life-tables. J R Stat Soc (B) 34: 187-220
9. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S and Bastert G (1992) Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 10: 1534-1539
10. Diel IJ, Kaufmann M, Costa SD and Bastert G (1994) Monoclonal antibodies to detect breast cancer cells. In: Important Advances in Oncology. DeVita VT, Hellman S and Rosenberg SA. (eds), pp. 143-164. Lippincott: Philadelphia
11. Diel IJ, Kaufmann M, Costa SD, Holle R, Von Minckwitz G, Solomayer EF, Kaul S and Bastert G (1996) Breast cancer patients with micrometastatic tumor cells in bone marrow at primary surgery - prognostic impact in comparison to nodal status. J Natl Cancer Inst 88: 1652-1658
12. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennely JJ and Andreasen P (1990) Urokinase plasminogen-activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
13. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ and Andreasen PA (1994) Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer Res 74: 2276-2280
14. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ and Duffy MJ (1995) Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600
15. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F and Klijn JG (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
16. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F and Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
17. Foekens JA, Look MP, Peters HA, van-Putten WL, Portengen H and Klijn JG (1995) Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756
18. Foucre D, Bouchet C, Hacene K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A and Oglobine J (1991) Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumors. Br J Cancer 64: 926-932
19. Frassica FJ and Sim FH (1988) Pathogenesis and prognosis. In: Diagnosis and Management of Metastatic Bone Disease. Sim FH. (ed.), p. 16. Raven Press: New York
20. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB and Verspaget HW (1994) Urokinase receptor and colorectal cancer survival (letler). Lancet 344: 401-402
21. Grundahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
22. Grondahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Ronne E, Dano K, Klijn JGM, Brünner N and Foekens JA (1995) Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087
23. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW and Schildberg FW (1995a) Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med 1: 1035-1039
24. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U and Schildberg FW (1995b) Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13: 2084-2093
25. Henderson BR, Tansey WP, Phillips SM, Ramshaw IA and Kefford RF (1992) Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Cancer Res 52: 2489-2496
26. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W and Graeff H (1990) Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
27. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
28. Jamshidi K, Swaim WR and Raisz G (1980) A new trephine for closed bone marrow biopsy. Acta Haemat 64: 216
29. Kaul S, Windecker S and Bastert G (1989) Monoclonal antibodies reactive with tumor-associated epitopes of breast mucin glycoproteins Proc Am Assoc Cancer Res 30: 349
30. Kramer MD, Vettel U, Schmitt M, Reinartz, J, Brunner G and Meissauer A (1992) Monoclonal antibodies against plasminogen activators and plasminogen. Fibrinolysis 6 (suppl. 4): 103-111
31. Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet J-C, McKinna A, Powles TJ and Coombes RC (1987) Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 295: 1093-1096
32. Mayer M (1990) Biochemical and biological aspects of the plasminogen activator system. Clin Biochem 23: 197-211
33. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U and Siewert JR (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907
34. Needham GK, Nicholson S, Angus B, Farndon JR and Harris AL (1988) Relationship of membrane-bound tissue type and urokinase type-plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Cancer Res 48: 6603-6607
35. Orr FW, Kostenuik P, Sanchez-Sweatman OH and Singh G (1993) Mechanism involved in the metastasis of cancer to bone. Breast Cancer Res Treat 25: 151-163
36. Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ and Rosen PP (1991) Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res 51: 2706-2709
37. Ossowski L, Russo-Payne H and Wilson EL (1991) Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 51: 274-281
38. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR and Riethmüller G (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85: 1419-1424
39. Pedersen H, Brünner N, Francis D, Osterlind K, Ronne E, Hausen HH, Dano K and Grondahl-Hansen J (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675
40. Pyke C, Graem N, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Brunner N and Dano K (1993) Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911-1915
41. Riesenberg R, Oberneder R, Kriegmair M, Epp M, Bitzer U, Hofstetter A, Braun S, Riethmüller G and Pantel K (1993) Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry 99: 61-66
42. Rosen PR, Groshen S, Saigo PE, Kinne DW and Hellman S (1989) A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7: 355-366
43. Schlimok G, Funke I, Holzmann B, Göttlinger G, Schmidt G, Häuser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H and Riethmüller G (1987) Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 84: 8672-8676
44. Schmitt M, Jänicke F and Graeff H (1990) Tumor-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis 1: 695-702
45. Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L and Graeff H (1992) Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 373: 611-622
46. Untch M, Harbeck N and Eiermann W (1988) Micrometastases in bone marrow in patients with breast cancer (letter). Br Med J 296: 290
47. Werner M, Kaul S and Bastert G (1988) Biochemical characterization of the mucin like tumor associated antigen TAG-12. J Cancer Res Clin Oncol 114: 59